(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/249641 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/36* (2006.01)
A61K 9/50 (2006.01) *A61P 3/00* (2006.01)
A61K 31/00 (2006.01) *A61P 9/00* (2006.01)
A61K 47/10 (2017.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/EP2020/066149

(22) International Filing Date:
10 June 2020 (10.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **APHAIA PHARMA IP AG** [CH/CH]; Bahnhofstrasse 28, 6300 Zug (CH).

(72) Inventors: **BOLZ, Steffen-Sebastian**; Schönbichlstrasse 166, 82211 Herrsching (DE). **DEUSCH, Kai**; Schlederloh 14, 82057 Icking (DE).

(74) Agent: **HABERMANN, HRUSCHKA & SCHNABEL**; Montgelasstr. 2, 81679 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING ENTEROKINE-RELEASING SUBSTANCES IN MULTIPLE DOSAGE FORMS IN COMBINATION WITH GELLING AGENTS




Fig. 1

(57) Abstract: The present invention relates to pharmaceutical compositions and pharmaceutical articles comprising such compositions wherein the compositions comprise multiple dosage forms each comprising a core and an enteric coating, wherein the core comprises at least one compound stimulating enteroendocrine cells to release at least one enterokine, wherein the size of the dosage forms, with respect to the largest dimension of the dosage forms, provides for entry of the dosage forms into the intestine of a subject independent of gastric emptying mechanisms, and wherein the composition further comprises one or more gelling agents. The invention also relates to the treatment and/or prevention of conditions amenable to stimulation of enterokine release by enteroendocrine cells.

WO 2021/249641 A1

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*